Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
 |
Food and Drug Administration - December 19, 2008
Richard Klein & Kimberly Struble
On December 19, 2008 FDA approved Ziagen (abacavir) 300 mg scored tablets with corresponding dosing information for pediatric patients weighing 14 kg or more using the scored tablet.
The Dosage and Administration and the Clinical Pharmacology sections were revised as follows:
2 DOSAGE AND ADMINISTRATION
2.2 Pediatric Patients
The recommended oral dose of ZIAGEN Oral Solution in HIV‑1‑infected pediatric patients >3 months of age is 8 mg/kg twice daily (up to a maximum of 300 mg twice daily) in combination with other antiretroviral agents.
ZIAGEN is also available as a scored tablet for HIV‑1‑infected pediatric patients weighing >14 kg for whom a solid dosage form is appropriate. Before prescribing ZIAGEN Tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow ZIAGEN Tablets, the oral solution formulation should be prescribed. The recommended oral dosage of ZIAGEN Tablets for HIV‑1‑infected pediatric patients is presented in Table 1.
| Weight
(kg) |
Dosage Regimen Using Scored Tablet | Total
Daily Dose |
|
|---|---|---|---|
| AM Dose | PM Dose | ||
12 CLINICAL PHARMACOLOGY
12.3 Pharmacokinetics
Pediatric Patients: The pharmacokinetics of abacavir have been studied after either single or repeat doses of ZIAGEN in 68 pediatric patients. Following multiple‑dose administration of ZIAGEN 8 mg/kg twice daily, steady-state AUC (0-12 hr) and Cmax were 9.8 ± 4.56 mcg•hr/mL and 3.71 ± 1.36 mcg/mL (mean ± SD), respectively [see Use in Specific Populations (8.4)]. In addition, to support dosing of Ziagen scored tablet (300 mg) for pediatric patients 14 – > 30 kg, analysis of actual and simulated pharmacokinetic data indicated comparable exposures are expected following administration of 300 mg scored tablet and the 8 mg/kg dosing regimen using oral solution.
Ziagen. a member of the Nucleoside Reverse Transcriptase Inhibitor (NRTI) class, is a product of GlaxoSmithKline.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
081219
FD081206
SOURCE: Food and Drug Administration (FDA).
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .